• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Hill Path Capital Partners Lp was granted 1,902 shares (SEC Form 4)

    1/3/24 4:49:59 PM ET
    $SEAS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SEAS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SeaWorld Entertainment, Inc. [ SEAS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/31/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1)(2) 12/31/2023 A 1,902(3) A $0.00 70,265 I By Scott Ross
    Common Stock(1)(2) 5,885,065 I By Hill Path Capital Partners LP(4)
    Common Stock(1)(2) 176,201 I By Hill Path Capital Co-Investment Partners LP(5)
    Common Stock(1)(2) 6,109,961 I By Hill Path Capital Partners Co-Investment E LP(6)
    Common Stock(1)(2) 402,017 I By Hill Path Capital Partners Co-Investment E2 LP(7)
    Common Stock(1)(2) 1,334,162 I By Hill Path Capital Partners-H LP(8)
    Common Stock(1)(2) 83,900 I By Hill Path Capital Partners Co-Investment S LP(9)
    Common Stock(1)(2) 10,518,006 I By HEP Fund LP(10)
    Common Stock(1)(2) 2,695,994 I By HM Fund LP(11)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners-H LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital Co-Investment Partners LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners Co-Investment E LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners Co-Investment E2 LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners GP LLC

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital Partners E GP LLC

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Investment Holdings LLC

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hill Path Capital LP

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    ROSS SCOTT I

    (Last) (First) (Middle)
    150 EAST 58TH STREET
    33RD FLOOR

    (Street)
    NEW YORK NY 10155

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. This Form 4 is filed jointly by Hill Path Capital Partners LP ("Hill Path Capital"), Hill Path Co-Investment Partners LP ("Hill Path Co-Investment"), Hill Path Capital Partners-H LP ("Hill Path H"), Hill Path Capital Partners Co-Investment E LP ("Hill Path E"), Hill Path Capital Partners Co-Investment E2 LP ("Hill Path E2"), Hill Path Capital Partners Co-Investment S LP ("Hill Path S"), HEP Fund LP ("HEP Fund"), HM Fund LP ("HM Fund"), Hill Path Capital Partners GP LLC ("Hill Path GP"), Hill Path Capital Partners E GP LLC ("Hill Path E GP"), Hill Path Capital Partners S GP LLC ("Hill Path S GP"), HE GP LLC ("HE GP"), HM GP LLC ("HM GP"), Hill Path Investment Holdings LLC ("Hill Path Investment Holdings"), Hill Path Capital LP ("Hill Path"), Hill Path Holdings LLC ("Hill Path Holdings") and Scott Ross ("Mr. Ross," and collectively with the aforementioned entities, the "Reporting Persons").
    2. To enable the Reporting Persons to gain access to the Securities and Exchange Commission's electronic filing system (which only accepts a maximum of 10 joint filers per report), this report is the first of two identical reports relating to the same transactions being filed with the Securities and Exchange Commission. Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group along with HAT Fund LP and HAT Fund II LP, which do not beneficially own any shares of Common Stock, that collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock. Mr. Ross is also a director of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
    3. Granted under the Issuer's 2017 Omnibus Incentive Plan and vests 100% immediately.
    4. Shares of Common Stock owned directly by Hill Path Capital. Hill Path GP, as the general partner of Hill Path Capital, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Capital. Hill Path Investment Holdings, as the managing member of Hill Path GP, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Capital. Hill Path, as the investment manager of Hill Path Capital, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Capital. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Capital. Mr. Ross, as the managing partner of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Capital.
    5. Shares of Common Stock owned directly by Hill Path Co-Investment. Hill Path GP, as the general partner of Hill Path Co-Investment, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Co-Investment. Hill Path Investment Holdings, as the managing member of Hill Path GP, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Co-Investment. Hill Path, as the investment manager of Hill Path Co-Investment, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Co-Investment. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Co-Investment. Mr. Ross, as the managing partner of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path Co-Investment.
    6. Shares of Common Stock owned directly by Hill Path E. Hill Path E GP, as the general partner of Hill Path E, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E. Hill Path Investment Holdings, as the managing member of Hill Path E GP, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E. Hill Path, as the investment manager of Hill Path E, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E. Mr. Ross, as the managing partner of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E.
    7. Shares of Common Stock owned directly by Hill Path E2. Hill Path E GP, as the general partner of Hill Path E2, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E2. Hill Path Investment Holdings, as the managing member of Hill Path E GP, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E2. Hill Path, as the investment manager of Hill Path E2, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E2. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E2. Mr. Ross, as the managing partner of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path E2.
    8. Shares of Common Stock owned directly by Hill Path H. Hill Path GP, as the general partner of Hill Path H, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path H. Hill Path Investment Holdings, as the managing member of Hill Path GP, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path H. Hill Path, as the investment manager of Hill Path H, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path H. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path H. Mr. Ross, as the managing partner of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path H.
    9. Shares of Common Stock owned directly by Hill Path S. Hill Path S GP, as the general partner of Hill Path S, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path S. Hill Path Investment Holdings, as the managing member of Hill Path S GP, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path S. Hill Path, as the investment manager of Hill Path S, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path S. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path S. Mr. Ross, as the managing partner of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by Hill Path S.
    10. Shares of Common Stock owned directly by HEP Fund. HE GP, as the general partner of HEP Fund, may be deemed to beneficially own the shares of Common Stock owned directly by HEP Fund. Hill Path Investment Holdings, as the managing member of HE GP, may be deemed to beneficially own the shares of Common Stock owned directly by HEP Fund. Hill Path, as the investment manager of HEP Fund, may be deemed to beneficially own the shares of Common Stock owned directly by HEP Fund. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by HEP Fund. Mr. Ross, as the managing member of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by HEP Fund.
    11. Shares of Common Stock owned directly by HM Fund. HM GP, as the general partner of HM Fund, may be deemed to beneficially own the shares of Common Stock owned directly by HM Fund. Hill Path Investment Holdings, as the managing member of HM GP, may be deemed to beneficially own the shares of Common Stock owned directly by HM Fund. Hill Path, as the investment manager of HM Fund, may be deemed to beneficially own the shares of Common Stock owned directly by HM Fund. Hill Path Holdings, as the general partner of Hill Path, may be deemed to beneficially own the shares of Common Stock owned directly by HM Fund. Mr. Ross, as the managing member of each of Hill Path Investment Holdings, Hill Path and Hill Path Holdings, may be deemed to beneficially own the shares of Common Stock owned directly by HM Fund.
    Hill Path Capital Partners LP, By: Hill Path Capital Partners GP LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital Partners-H LP, By: Hill Path Capital Partners GP LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital Co-Investment Partners LP, By: Hill Path Capital Partners GP LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital Partners Co-Investment E LP, By: Hill Path Capital Partners E GP LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital Partners Co-Investment E2 LP, By: Hill Path Capital Partners E GP LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital Partners GP LLC, By: Hill Path Investment Holdings LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital Partners E GP LLC, By: Hill Path Investment Holdings LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Investment Holdings LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    Hill Path Capital LP, By: Hill Path Holdings LLC, By: /s/ Scott Ross, Managing Partner 01/03/2024
    By: /s/ Scott Ross 01/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SEAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEAS

    DatePrice TargetRatingAnalyst
    12/14/2023$60.00 → $57.00Overweight → Equal-Weight
    Morgan Stanley
    11/1/2023$67.00 → $57.00Neutral
    JP Morgan
    7/24/2023$75.00 → $66.00Buy
    Goldman
    5/31/2023$75.00Buy
    Goldman
    5/25/2023Sector Weight
    KeyBanc Capital Markets
    4/20/2023$70.00Overweight
    Morgan Stanley
    7/13/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    4/26/2022$92.00Buy
    Rosenblatt
    More analyst ratings

    $SEAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lipman Nathaniel was granted 1,687 shares (SEC Form 4)

      4 - SeaWorld Entertainment, Inc. (0001564902) (Issuer)

      1/4/24 4:46:38 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Lipman Nathaniel

      3 - SeaWorld Entertainment, Inc. (0001564902) (Issuer)

      1/4/24 4:42:26 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hill Path Capital Partners Co-Investment S Lp was granted 1,902 shares (SEC Form 4)

      4 - SeaWorld Entertainment, Inc. (0001564902) (Issuer)

      1/3/24 4:51:05 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SEAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaWorld San Antonio Reveals Plans for the ALL-NEW Rescue Jr. Hub, a Kid-Friendly World of Discovery Packed with Interactive Play, Immersive Attractions and a One-Of-A-Kind Water Elements - Opening Spring 2025

      2025 Annual Passes are now available with the best benefits ever, including Aquatica for free, free parking, free guest tickets, in-park discounts and exclusive animal experiences; 2025 Annual Pass Members will also be the first to experience Rescue Jr. DOWNLOAD HIGH-RES IMAGES HERE  SAN ANTONIO, Sept. 30, 2024 /PRNewswire/ -- SeaWorld San Antonio today unveiled its plans for an ALL-NEW friendly world of discovery, the Rescue Jr. hub, set to open Spring 2025. This immersive, hands-on adventure zone will transport young guests into the heart of SeaWorld's animal rescue efforts, where they'll tackle immersive rides, conquer towering climbing structures, splash through vibrant water features a

      9/30/24 9:00:00 AM ET
      $PRKS
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Get Ready for Jaw-Dropping Adventures as SeaWorld's Ultimate Shark Experience Returns for 2024

      SeaWorld's week-long Ultimate Shark Experience celebrates sharks in its parks with once-in-a-lifetime fin-credible opportunities for guests of all ages, all while supporting shark conservation DOWNLOAD HIGH-RES IMAGES HERE ORLANDO, Fla., July 2, 2024 /PRNewswire/ -- SeaWorld is thrilled to unveil the return of its highly anticipated Ultimate Shark Experience ticket, available for purchase starting today. This special ticket provides guests with an exclusive opportunity to fully immerse themselves in a day filled with exciting and educational shark-focused activities. From goin

      7/2/24 8:00:00 AM ET
      $PRKS
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SeaWorld and Coca-Cola Say Cheers to 60 Years with New Celebration Sundays Featuring Exclusive Merchandise Giveaways for Pass Members and Complimentary Beverage Sampling for All Guests

      Coca-Cola Celebration Sundays at SeaWorld start Sunday, June 16th and continue the third Sunday of each month for the rest of the year ORLANDO, Fla., June 13, 2024 /PRNewswire/ -- Coca-Cola is toasting SeaWorld's 60th anniversary by partnering with the parks to host "Celebration Sundays," featuring free beverage sampling for all guests and exclusive, limited-edition co-branded merchandise giveaways for pass members, while supplies last. The events kick-off on Sunday, June 16 and will continue on the third Sunday of each month through the end of the year. Each month's merchandise giveaway will be a new collectible item that will be announced prior to that month's event. June's giveaway is a 2

      6/13/24 8:00:00 AM ET
      $PRKS
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SEAS
    SEC Filings

    See more
    • SeaWorld Entertainment Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - United Parks & Resorts Inc. (0001564902) (Filer)

      2/13/24 4:16:14 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SeaWorld Entertainment Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits (Amendment)

      8-K/A - SeaWorld Entertainment, Inc. (0001564902) (Filer)

      1/29/24 6:30:11 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SeaWorld Entertainment Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - SeaWorld Entertainment, Inc. (0001564902) (Filer)

      1/26/24 4:15:14 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SEAS
    Leadership Updates

    Live Leadership Updates

    See more
    • SeaWorld Launches 60th Anniversary Celebrations and Unveils "There's So Much More to Sea"

      Guests are invited to take advantage of limited time promotions on tickets and passes to join the celebrations, which kick off on March 21 with in-park parties and continue with thrilling new rides, shows and experiences coming this summer DOWNLOAD HIGH-RES IMAGES HERE ORLANDO, Fla., Feb. 5, 2024 /PRNewswire/ -- SeaWorld is turning 60 this year, and to celebrate, the world-class parks are throwing a party and marking the occasion throughout the year with all-new themed rides and attractions, exciting new presentations and shows, and plenty of other exclusive ticket and experience offers, plus limited-edition food and beverage items, merchandise and collectibles that will be announced in the

      2/5/24 8:00:00 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SeaWorld to Open Exciting One-Of-A-Kind Marine Life Themed Rides and Experiences for the Whole Family in Every Park in 2024

      Become a 2024 Pass Member and be the first to experience the new attractions before they open to the public; 2024 passes on sale now DOWNLOAD MEDIA ASSETS HERE ORLANDO, Fla., Sept. 28, 2023 /PRNewswire/ -- SeaWorld is thrilled to announce it will open one-of-a-kind marine life themed rides and attractions in every SeaWorld park in Spring 2024.  Guests to the award-winning parks in Orlando, San Antonio, and San Diego can look forward to epic journeys and experiences for the whole family that will leave them breathless, drenched, and utterly mesmerized.  Attractions include "Penguin Trek" at SeaWorld Orlando, an all-new family friendly coaster for guests 42-77 inches in height that will transp

      9/28/23 9:00:00 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SeaWorld Entertainment, Inc. Announces the Retirement of Michelle ("Chelle") Adams

      ORLANDO, Fla., July 3, 2023 /PRNewswire/ -- SeaWorld Entertainment, Inc. (NYSE:SEAS), a leading theme park and entertainment company, today announced that Chelle Adams, Chief Transformation Officer of SeaWorld Entertainment, Inc., intends to retire from SeaWorld in order to pursue personal opportunities effective August 4th, 2023. Ms. Adams will be available to the company over the coming months to ensure a smooth transition.  Marc Swanson, Chief Executive Officer of SeaWorld Entertainment, Inc. said, "On behalf of the entire Company, we want to thank Chelle for her contributions to the Company and wish her well." Chelle Adams said, "I appreciate the opportunity to have been part of the SeaW

      7/3/23 4:50:00 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SEAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SeaWorld Entertainment Inc.

      SC 13G - United Parks & Resorts Inc. (0001564902) (Subject)

      2/13/24 1:09:05 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by SeaWorld Entertainment Inc. (Amendment)

      SC 13G/A - SeaWorld Entertainment, Inc. (0001564902) (Subject)

      2/14/23 10:41:02 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by SeaWorld Entertainment Inc. (Amendment)

      SC 13D/A - SeaWorld Entertainment, Inc. (0001564902) (Subject)

      11/14/22 4:02:56 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SEAS
    Financials

    Live finance-specific insights

    See more
    • SEAWORLD ENTERTAINMENT, INC. ANNOUNCES FOURTH QUARTER AND FISCAL 2023 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

      ORLANDO, Fla., Feb. 8, 2024 /PRNewswire/ -- SeaWorld Entertainment, Inc. (NYSE:SEAS) announced today that it will release its fourth quarter and fiscal 2023 financial results before the market opens on Wednesday, February 28, 2024. In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the internet on Wednesday, February 28, 2024, at 9 a.m. Eastern Time. The release and the conference call can be accessed via the Company's website at www.SeaWorldInvestors.com or www.UnitedParksInvestors.com. For those unable to participate in the live webcast, a replay will be available beginning at approximately 12 p.m. Eastern Time on February 28, 20

      2/8/24 4:30:00 PM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEAWORLD ENTERTAINMENT, INC. ANNOUNCES THIRD QUARTER EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

      ORLANDO, Fla., Oct. 11, 2023 /PRNewswire/ -- SeaWorld Entertainment, Inc. (NYSE:SEAS) announced today that it will release its third quarter financial results before the market opens on Wednesday, November 8, 2023. In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the internet on Wednesday, November 8, 2023, at 9 a.m. Eastern Time. The release and the conference call can be accessed via the Company's website at www.SeaWorldInvestors.com. For those unable to participate in the live webcast, a replay will be available beginning at approximately 12 p.m. Eastern Time on November 8, 2023, under the "Events & Presentations" tab of www.S

      10/11/23 6:30:00 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SeaWorld Entertainment, Inc. Reports Second Quarter and First Six Months 2023 Results

      ORLANDO, Fla., Aug. 8, 2023 /PRNewswire/ -- SeaWorld Entertainment, Inc. (NYSE:SEAS), a leading theme park and entertainment company, today reported its financial results for the second quarter and first six months of fiscal year 2023. Second Quarter 2023 Highlights Attendance was 6.1 million guests, a decrease of approximately 0.1 million guests from the second quarter of 2022.Total revenue was $496.0 million, a decrease of $8.8 million or 1.7% from the second quarter of 2022.Net income was $87.1 million, a decrease of $29.6 million or 25.3% from the second quarter of 2022.Adjusted EBITDA[1] was $224.2 million, a decrease of $10.2 million or 4.4% from the second quarter of 2022.Total revenu

      8/8/23 6:30:00 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SEAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SeaWorld Entertainment downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded SeaWorld Entertainment from Overweight to Equal-Weight and set a new price target of $57.00 from $60.00 previously

      12/14/23 7:48:37 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • JP Morgan resumed coverage on SeaWorld Entertainment with a new price target

      JP Morgan resumed coverage of SeaWorld Entertainment with a rating of Neutral and set a new price target of $57.00 from $67.00 previously

      11/1/23 6:19:32 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman reiterated coverage on SeaWorld Entertainment with a new price target

      Goldman reiterated coverage of SeaWorld Entertainment with a rating of Buy and set a new price target of $66.00 from $75.00 previously

      7/24/23 10:10:47 AM ET
      $SEAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care